Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-24 @ 5:06 PM
Ignite Modification Date:
2025-12-25 @ 2:44 PM
NCT ID:
NCT04091750
Group ID:
EG000
Title:
Single Arm
Description:
Induction phase:
Nivolumab 3mg/kg IV plus Ipilimumab 1mg/kg IV every 3 weeks x 4 cycles (12 week period)
Cabozantinib 40mg PO daily for 12 weeks
Maintenance phase:
Nivolumab 480mg IV every 4 weeks for up to 92 weeks
Cabozantinib 40mg PO daily for up to 92 weeks
Maintenance therapy will continue for up to 92 weeks to complete 2 years total of treatment if tolerating therapy well and disease is controlled.
Nivolumab: Induction: 3mg/kg IV every 3 weeks x 4 cycles
Maintenance: 480mg IV every 4 weeks for up to 92 weeks
Ipilimumab: Induction: 1mg/kg IV every 3 weeks x 4 cycles
Cabozantinib: Induction and Maintenance: 40mg PO daily
Deaths Number Affected:
10
Deaths Number At Risk:
None
Serious Number Affected:
9
Serious Number At Risk:
14
Other Number Affected:
14
Other Number At Risk:
14
Study:
NCT04091750
Results Section:
NCT04091750
Adverse Events Module:
NCT04091750